RxDoctor Payments Data

Iris Joseph, NP

Psychiatric/Mental Health · Charlestown, MANPI 1932452513

Payments from drug & device makers

$472in general payments, 2019–2025

Across 7 payments — averaging $67.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$205
  • Tempus AI, Inc$96
  • Acadia Pharmaceuticals Inc$70
  • Neurocrine Biosciences, Inc.$62
  • Mylan Specialty L.p.$26
  • Lexicon Pharmaceuticals, Inc.$13

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$472 in reported general payments places this provider in the 60th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$243,757
Medicare patients
594
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$48,915
XareltoRivaroxaban20$5,533
BrilintaTicagrelor18$4,055
Mirtazapine66$2,987
Divalproex Sodium24$2,569
Metoprolol Succinate119$1,916
Lubiprostone11$1,694
Admelog SolostarInsulin Lispro15$1,330
Furosemide263$1,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,244
Atorvastatin Calcium95$979
Potassium Chloride51$783
Sertraline Hcl83$779
Latanoprost37$732
Duloxetine Hcl20$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$205$5,53320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Charlestown

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →